Gapping up
In reaction to earnings/guidance:
- CURV +11%, THO +7.2%, KC +5.7%, CPB +4.1%
Other news:
- DBVT +23.5% (positive topline results from Phase 3 EPITOPE Trial)
- ALDX +19.2% (achieves primary endpoint in phase 3 tranquility-2 trial)
- MNOV +11.9% (top-line results from phase 2 clinical trial of MN-166)
- NVAX +10.1% (FDA advisory committee recommends EUA for its COVID-19 vaccine)
- PASG +6.9% (cleared its Investigational New Drug application for PBML04)
- DTIL +5.3% (announces its latest program updates across its allogeneic CAR T pipeline)
- DOCU +4.6% (expands partnership with MSFT to accelerate anywhere work)
- WDC +4.1% (provides update on review of strategic alternatives)
- IMVT +3.3% (Achieves Alignment with FDA on Plans for Phase 3 Clinical Trials of Batoclimab)
- OCFT +2.3% (upsizes its share repurchase program)
- GENI +2% (stock offering)
- EIGR +1.3% (enters into $75 mln term loan agreement with Innovatus)
- LMDX +1% (achieved CE Mark for two new Fast Lab Solutions molecular tests)
Analyst comments:
- WFRD +3.9% (initiated with a Buy at Goldman)